Evercore ISI Group Initiates Coverage On vTv Therapeutics with Outperform Rating, Announces Price Target of $44
Benzinga Newsdesk 7 months ago
NewsPrice TargetInitiationAnalyst Ratings
Evercore ISI Group analyst Michael DiFiore initiates coverage on vTv Therapeutics (NASDAQ:VTVT) with a Outperform rating and announces Price Target of $44.
Evercore ISI Group analyst Michael DiFiore initiates coverage on vTv Therapeutics (NASDAQ:VTVT) with a Outperform rating and announces Price Target of $44.